


## PERSONAL INFORMATION



## Oriana Tabarrini

 Department of Pharmaceutical Sciences, university of Perugia

 +39 0755855139

 [oriana.tabarrini@unipg.it](mailto:oriana.tabarrini@unipg.it)

Sex Female | Nationality Italy

## EDUCATION, TRAINING AND WORK EXPERIENCE

2022	<b>Full Professor, CHIM08-Medicinal Chemistry</b> Department of Pharmaceutical Sciences, UNIPG
2002-2022	<b>Associate Professor, CHIM08-Medicinal Chemistry</b> Department of Pharmaceutical Sciences, UNIPG
1997-2002	<b>Confirmed Research Assistant (NC07-Pharmaceutic)</b> Department of Pharmaceutical Sciences, UNIPG
1994-1997	<b>Research assistant (NC07-Pharmaceutic)</b> Department of Pharmaceutical Sciences, UNIPG
1990	<b>Habilitation as teacher of Chemistry (classe di Concorso XV)</b> competition for professorship DM 23/3/90
1987-1994	<b>Post-graduate researcher</b> with research grant from MEDIOLANUM Farmaceutici S.r.L (then S.p.A.) entitled " Synthesis of heterocyclic derivatives of biological interest"
1986	<b>Habilitation as Pharmacist</b>
1986	<b>Degree in Pharmaceutical Chemistry and Technology,</b> summa cum laude University of Perugia

## COORDINATION, ATTENDENCE IN COMMITTEES AND OFFICIAL APPOINTMENTS

December 2022-present	Coordinator of the doctorate in Pharmaceutical Sciences
September 2022-present	Member of the scientific committee of PROVIDER ECM-UNIPG
November 2021-present	Member of group for the sustainability analysis of the UNIPG educational offer
March 2021-present	Member of the UNIPG-committee for attribution/organization of the 24 CFU required for teaching
January 2020 -2025	Member of the Support Observatory of the Vice Rector of UNIPG
2019-2022	Scientific Coordinator POT-Pharmacy (Plan for Orienting and Tutoring)
2019-present	Member of the Scientific Committee of the University College of Merit of the ONAOSI Foundation-Perugia
2017-2022	Coordinator of the Master Degree in Pharmaceutical Chemistry and Technology (CTF), DSF-UNIPG
2017-2022	Member of the Teaching Committee of DSF-UNIPG
2016-2020	Member of COST Action CA15135- Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)
2015-present	Local Coordinator of the International European Network of PhD in Medicinal Chemistry, Paul Ehrlich European Ph.D (58 European Universities) <a href="http://www.pehrlichmedchem.eu/members.html">http://www.pehrlichmedchem.eu/members.html</a> 2014-2016 Elected member of the board of the DSF-UNIPG
2014-2016, and 2019	
2015-2017	Delegate of the DSF-UNIPG for Students Orientation
2009-2017	Delegate of the Faculty of Pharmacy and then DSF-UNIPG for Special Needs and Differently-able students
2014-2022	Teaching staff member of the PhD program in "Pharmaceutical Sciences", UNIPG
2012- present	Founder member of the International Network "SeS Redox and Catalysis"

2011-2016	Member of the Steering Committee of the Master Degree in CTF, DSF-UNIPG
2007-2016	Coordinator of the teaching activities of the International PhD course in Chemistry and Technology of Drugs and "Pharmaceutical Sciences" UNIPG
2011-2016	Coordinator of the Evaluation Committee of the annual reports of PhD students- UNIPG
2011- present	Member of the committee for the allocation of part-time students, DSF-UNIPG
2009- present	Member of the committee of the DSF-UNIPG (initially Faculty of Pharmacy), for the evaluation of Erasmus and Erasmus Placement applications
2009-2017	Member of CLA board (University Language Centre), UNIPG
2007-2012	Elected member of SCI/Umbria Section
2002-2014	Teaching staff member of the PhD program in Pharmaceutical Chemistry and Technology, International (Perugia, Vienna e Granada ) and National profiling, UNIPG
	Member of SCI-Medicinal Chemistry Division

### TEACHING ACTIVITY

Since 1987, member of commissions for the exams, gave seminars and made integrative teaching activities.

Since 1994, teacher in various courses within the CHIM-08 disciplinary scientific sector of the Faculty of Pharmacy and then of the DSF, such as CTF, Pharmacy, Pharmaceutical Biotechnology, Quality Control in SIFA and Scientific Informant on Drugs, as specified below.

Participation in numerous commissions of the State Exams for the qualification to the profession of Pharmacist and those for the qualification to the profession of Chemist.

Since 2017, in addition to being coordinator of the master's degree course in CTF, I have been a member of the Didactic Commission of the DSF and from March 2021 of the University Commission for the acquisition of 24 credits for teaching.

With regard to the results of the evaluation by students, the courses I hold have always received a positive evaluation with values above the average of the CdL in CTF.

2018/2019 - present	Medicinal Chemistry I (CTF, 9 CFU) Analysis of drugs (CTF, 3+2, Co-teaching)
2020, 2026	Cycle of Lessons at University College of Merit of the ONAOSI Foundation-Perugia: "Farmaci antivirali: un grande impegno per annientare il più piccolo nemico dell'uomo"
2017-2022	Member of the commission for the evaluation of the professional training of students of the CdL di CTF
2016/2017 and 2017/2018	Medicinal Chemistry I (CTF, 9 CFU) Analysis of drugs (Pharmacy, 2+3L CFU)
2015/2016	Medicinal Chemistry I (CTF, 9 CFU)
2014/2015	Analysis of drugs (CTF, 3+3L CFU)
2011/2012 – 2013/2014	Analysis of drugs (CTF, 3+3L CFU) Medicinal Chemistry and Toxicology I (Pharmacy, 11 CFU)
2010/2011	Analysis of drugs (CTF, 3+3L CFU) Biotechnological Medicinal Chemistry (Pharmaceutical Biotechnology, 3 CFU)
2005/2006-2009/2010	Medicinal Chemistry (ISF, 10 CFU) Medicinal Chemistry (CQ on SIFA, 10 CFU, AA 2009-2010) Biotechnological Medicinal Chemistry (Pharmaceutical Biotechnology, 3 CFU), 3 CFU)
2002/2003- 2004/2005	Analysis of drugs (CTF, 2+3L CFU) Medicinal Chemistry (ISF, 10 CFU)
1998/1999-2001/2002	Analysis of drugs (CTF, 2+3L CFU)
1998/1999-2001/2002	Integrative teaching activity for Analysis of Drugs III and Medicinal Chemistry and Toxicology II (CdL Pharmacy, Faculty of Pharmacy), Preparation, Extraction and Synthesis Laboratory of Drugs and Medicinal Chemistry and Toxicology II (CdL CTF), Faculty of Pharmacy
1994/1995-1997/1998	Integrative teaching activity for Analysis of Drugs (CdL CTF), Analysis of Drugs III and Medicinal Chemistry and Toxicology II (CdL Pharmacy, Faculty of Pharmacy)
1987/1988-present	Member of the commissions of the exams of the courses I was the owner and those for which I did supplementary teaching activities and others in the CHIM-08 sector. Member of the graduation commissions (all those in which I was thesis supervisor and from 2017, president of all the CTF graduation commissions)

### TEACHING ACTIVITIES AT FOREIGN UNIVERSITIES

2019 (4 hours)	"New strategies to identify antiviral and antitubercular agents", Department of Pharmaceutical Chemistry – Ljubljana University, Ljubljana, Slovenia (Erasmus Plus). Invited by Prof Danijel Kikelj from 1-12-2019 to 4-12-2019
2016 (8 hours)	"Recent Advance in the Identification of Tat-Mediated Transactivation Inhibitors: Progressing Toward a Functional cure of HIV" , Part I and Part II; "Allosteric HIV-1 Ribonuclease H inhibitors: Studies on Cycloheptathiophene-3-Carboxamide Derivatives"; "Quinolone derivatives as privileged structure" . Department of Organic Chemistry, Faculty of Pharmacy, Wrocław University of Technology, PL (Erasmus Plus Program). Invited by Prof Elzbieta Wojaczynska from 10-04-2016 to 13-04-2016

- 2016 (8 hours) "Innovative strategies to treat HIV infection", Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (Erasmus Plus program). Invited by Prof Uriarte Villares Eugenio from 26-09-2016 to 28-09-2016
- 2006 (8 hours) "Aptamers: basic research, drug development, and clinical applications"; " Hepatitis C virus (HCV): the health problem"; " Blocking HIV replication by targeting Tat-TAR complex", School of Pharmacy Jagellonian University Krakow –PL (LLP-Erasmus Program). Invited by Prof. Prof Katarzyna Kieć-Kononowicz from 04-09-2006 to 07-09-2006

#### ABILITY TO INVOLVE AND TRAIN YOUNG RESEARCHERS

- 2024-2025 Referent of research fellowships (Dr. Maria Giulia Nizi, Dr Martina Pacetti, Dr. Giada Cernicchi, Dr. Giulia Ianni, Andrea Dragan)
- 2023 Scientific referent of AIRC fellowship (Dr. Maria Giulia Nizi)
- 2018-2021 Referent of RTD B (assistant researcher of type B) (Dr. S. Massari)
- 2019 Scientific referent of a post-degree grant financed by Tabarrini's funds (3 months, Dott. A. Mazzarella)
- 2015-2018 Referent of RTD A (assistant researcher of type A) (Dott. S. Massari)
- 2016 Scientific referent of a post-degree grant financed by Tabarrini's funds (2 months, Dott. G. Santucci)
- 2014 Scientific referent of a post-Doc grant financed by CINMPIS (3 months, Dott. L. Sancineto)
- 2013 Scientific referent of a research grant financed by CINMPIS (12 months, Dott. L. Sancineto)
- 2012 Scientific referent of a Co.Co.Co. entitled "Aggiornamento e verifica di un database di composti sintetizzati in house" financed by Tabarrini's funds (5 months, Dott. S. Massari)
- 2009 Scientific referent of a post-degree grant financed by Tabarrini's funds (3 months, Dott. E. Coppari)
- 2005-present Supervisor of 7 PhD students (Pieroni M, Massari S, Sancineto L, Desantis J, M. G. Nizi, Sarnari C. F. Brogi) and Tutor of 4 PhD students (Lorenzini C, Miao H, Dall'Uomo M, Manfroni G), of which five are currently Associate Professors and one is post-doc, at various Universities, and therefore with a brilliant and independent career.
- 2004-present Supervisor of many incoming and outgoing ERASMUS students
- 1989/1990-present Supervisor and/or co-supervisor of many experimental master thesis, mainly of students from the CdL in CTF, but also Pharmacy and Pharmaceutical Biotechnology
- 1987/1988-2001/2002 Seminars activities for the course of Medicinal Chemistry and Toxicology II (CdL Pharmacy, Faculty of Pharmacy)

#### EXTERNAL REFEREE

- Member of the examining committee for Doctoral Thesis in Pharmaceutical Sciences: Department of Biotechnology, Chemistry and Pharmacy-**Siena (2010, 2012, 2020, 2023)**; Department of Drug Sciences- **Padova (2018, 2019, 2025, 2026)**; Faculty of Pharmaceutical Sciences -**Ghent (Belgium) (2019)**; Universidad CEU San Pablo, **Madrid (2019)**; Department of Chemistry and Technology of Drug-**Roma (2019)**; Department of Neurosciences-**Firenze (2016)**, University of **Palermo (2022, 2023)**
- Member of the selection board for comparative evaluation within the 03/D1, SSD CHIM/08 – Medicinal Chemistry: **2025**, reseaecher RTT (Palermo) **2024**, full professor (University of Siena); researcher RTTT (University of Padova), researcher RTDB (University of Parma), **2023**, researcher RTDA (University Siena,); **2022** and **2023**, researcher RTDA (University La Sapienza-Roma); **2020**, researcher RTDB (University of Padova, Dipartimento di Scienze del Farmaco); **2017**, researcher RTDA (Università degli studi di Firenze, Dipartimento di NEUROFARBA); **2002**, Assistant professor (Facoltà di Farmacia, Università di Cagliari); Assistant professor (Dipartimento di Scienze Farmaceutiche, Università di Firenze).
- Referee of projects submitted to the National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme (JRS) 2020/21, Hong Kong, November **2020**
- Evaluator of application for promotion from associate professor to "Professor In" at the Trinity College di Dublino, November **2020**
- Referee of a projects submitted EU-project ISIDORe, April **2023**

#### ORIENTATION AND TUTORING ACTIVITIES

Over the years, the orientation activity has involved numerous presentations of DSF courses and lessons at second grade schools, and participation to numerous orientation salons. The welcome in my research laboratory of secondary school students thanks to the alternation school-work projects (ASL), now courses for transversal skills (PCTO), represents a further action of conscious orientation to the course of study.

- **2020-2021, Scientific coordinator of the project POT-Pharmacy**, financed by University of Perugia
- **2019-2020, Scientific coordinator of the project POT-Pharmacy** (Plan for Orienting and Tutoring), financed by MIUR, in collaboration with 14 Universities
- **2015-2017, Delegate of the DSF** for orientation activities  
I coordinate all the orientation and tutoring actions foreseen by the POT project, aimed at increasing aware enrollments and promoting students' careers.

#### COORDINATOR OF ERASMUS AGREEMENTS

- Universidad San Pablo CEU, Facultad de Farmacia, Madrid (SPAIN)
- Faculty of Pharmaceutical Sciences, Lubjan (SLOVENIA)
- Ghent University, Ghent (BELGIUM)
- University of Chemistry and Technology, UCT, Prague (CZECH REPUBLIC)
- Universitat Ramon Llull IQS, Barcellona (SPAIN)

#### SCIENTIFIC COORDINATOR AND MEMBER OF RESEARCH PROJECTS

2024 (PNRR)	Cascade Open Call 2023 (COC-1- 2023-CNR): "PANVIRIDE", Starting date: April 2024, duration 18 months, <b>Deputy PI, and Scientific Unit Coordinator</b>
2024 (PNRR)	Cascade Open Call (CN RNA & GENE THERAPY): "Innovative Methods for RNA-Targeting Molecules Evolution" Starting date June 2024, duration 16 months, <b>Member of unit research</b>
2023 (PRIN 2022)	Fighting SARS-CoV-2: discovery of preclinical candidates through target- and phenotype-based approaches" Starting date October 2023, duration 24 months <b>Unit coordinator and co-PI</b>
2022 (SIS AIRC)	Overcoming breast cancer resistance to hormone-based therapy by targeting the PARP12 enzyme", duration 5 years. <b>External collaborator</b>
2020 (FISR 2020-COVID)	"A Small molecule To Overcome Present and future COronaVirus Diseases (STOP Covid)", cod. FISR2020IP_03296, starting date September 2021, duration 6 months. <b>Scientific coordinator</b>
2019 (Sterling SPA)	"Synthesis of a small molecule as tyrosine kinase inhibitor", cod. 3STERLING18OT, starting date February 2019, duration 6 months. <b>Scientific coordinator</b>
2018 (Ricerca di base)	Università degli studi di Perugia, cod. 3RICBASE2018_TABARRINI, starting date June 2018, duration 24 months. <b>Scientific coordinator</b>
2016 (Santucci e Partners)	"Identificazione di agenti alternativi nel trattamento dell'infezione da HIV", cod. 3SANTPATOT, starting date December 2016, duration 2 months. <b>Scientific coordinator</b>
2015 ( Fondazione Cassa Risparmio Perugia (FCRP) - Ricerca Scientifica e Tecnologica 2015)	"Sviluppo di farmaci anti-influenzali che interferiscono con il corretto assemblaggio delle subunità polimerasiche", cod. 2015.0342.021, starting date June 2015, duration 12 months. <b>Scientific coordinator</b>
2015 (Ricerca di base)	"Sviluppo di inibitori dell'interazione PA/PB1 della polimerasi dell'influenza come nuovi agenti antivirali", cod. 3RICBASEOT, starting date May 2015, duration 24 months. <b>Scientific coordinator</b>
2015-2020 (Academy of Finland)	"ADP-ribosyltransferase inhibitors as chemical probes and drugs" cod. 287063 starting date September 2015, duration 5 years, e cod. 29408, starting date September 2015, duration 3 years. <b>Scientific collaborator</b>
2014 ( Alexander von Humboldt foundation)	"Targeting HIV-1 trans-activation responsive RNA by halogenated molecules". In collaboration with P. Carloni, German Research School for Simulation Sciences Jülich, (German) and M. Kolar, University of Chemistry and Technology, Technicka, Prague (Czech Republic), duration 24 months. <b>Scientific collaborator</b>
2014 ( CINMPIS (Interuniversity Consortium)	"Design and Synthesis of Se and S derivative for the treatment of HIV infection", starting date May 2014, duration 3 months. <b>Scientific coordinator</b>
2013 (CINPIS)	"Design and Synthesis of Se and S derivative for the treatment of HIV infection". Starting date March 2013, duration 12 months. <b>Scientific coordinator</b>
2012 (PRIN 2010/2011)	"Bloccare la replicazione di HIV-1 attraverso un approccio rivolto verso diversi bersagli molecolari", starting date February 2013, duration 36 months. <b>Member of unit research</b>
2010 ( FCRP-Bando a tema ricerca di base 2010)	"Sviluppo di nuovi farmaci basati sul metabolismo del triptofano per il trattamento della sclerosi multipla", cod. 2010.011.0408, starting date March 2011, duration 18 months. <b>Scientific coordinator</b>
2009 ( Istituto Superiore di Sanità (ISS)-Program for AIDS research 2009)	"Targeting HIV transcription to control infection and to purge post-integrative latency", cod. upr-2009-1301355, starting date December 2010, duration 24 months. <b>Scientific coordinator</b>

- 2009 (ISS) "Come contrastare la pandemia influenzale: individuazione di nuovi farmaci efficaci", starting date November 2009, duration 18 months. **Scientific coordinator** for the "design and synthesis of flu polymerase inhibitors"
- 2008 (PRIN 2008) "Progettazione, sintesi e attività biologica di agenti anti-HIV che interagiscono con target virali e cellulari innovativi (in, HAT, Tat/TAR, cdk9, RNasi H, dimerizzazione dell'RT, DDX3, CXCR4 e CCR5)", cod. 2008ce75sa\_002, starting date March 2010, duration 24 months. **Member of unit research**
- 2006 (PRIN 2006) "Sviluppo di derivati chinolonici e di altri eterocicli azotati come agenti anti-HIV: progettazione, sintesi, studio delle interazioni con nuovi target (in, RNasi H, Tat/RNA) e modulazioni della farmaco-resistenza (NNRTI)", cod. 2006030809, duration 24 mesi. **Member of unit research**
- 2004 (PRIN 2004) "Optimization of anti-HIV quinolone derivatives as inhibitors of Tat-driven transactivation", cod. 2004037792\_006, duration 24 months. **Member of unit research**
- 2002 (PRIN 2002) "Ottimizzazione strutturale di chinoloni anti-HIV", cod. 2002038878\_004, duration 24 months. **Member of unit research**
- 2000 (COFIN 2000) "Progettazione, sintesi e valutazione biologica di nuovi agenti anti-AIDS", cod. mm03262952\_005, duration 24 months. **Member of unit research**
- 1999 (COFIN 1999) "New agents for the therapy of AIDS and related diseases: design, synthesis and biological assays", cod. 9903265257\_006. **Member of unit research**
- 1997 (COFIN 1997) "Progettazione, sintesi e valutazione biologica di nuovi farmaci", cod. 9703028183-003, duration 24 months. **Member of unit research**

### SCIENTIFIC RESEARCH

The scientific activity, documented by 128 publications in international journals with high IF (of which 33 published in JMedChem), five patents, mainly concerned the design, synthesis, characterization and biological evaluation of small molecules as chemotherapeutic agents, with particular focus on antivirals. The studies initially concerned compounds with antibacterial activity thanks to scholarships funded by Mediolanum Farmaceutici. The research activity was then directed to the development of antiviral agents, starting the line of research on HIV, HCV and Influenza. Other viruses of interest have been HCMV, HPV, and Dengue and in the last year SARS-CoV2. Another line of research involved the development of a broad class of efflux pump inhibitors to counteract bacterial resistance. Less ongoing research lines have been K-channel modulators, p38 $\alpha$  MAPK inhibitors, and compounds with antitubercular activity. Over the years I have also been involved in the development of anticancer agents and recently I started a new line of research with very promising compounds that inhibit PARP enzymes. The interest in molecules capable of selectively interacting with RNA, not only viral, has also guided studies towards neurodegenerative diseases such as Huntington, and I was the Guest Editor of the special issue on Molecules: "RNA: Still an Under-Exploited Drug Target." All the researches were performed in collaborations with national and international groups responsible for biological evaluation and/or computational studies.

#### Main scientific collaborators

**ANTIVIRALS:** *Johan Neyts*, *Christophe Pannecouque*, *Steve de Jonghe*, Rega Institute for Medical Research, Leuven (Belgium); *Enzo Tramontano*, Dipartimento di Scienze Applicate ai Biosistemi, Cittadella Universitaria S.P. Monserrato-Cagliari (Italy); *Giorgio Palù*, *Arianna Loregian*, Department of Molecular Medicine, University of Padova (Italy); *Stuart Le Grice*, Head Center of Excellence in HIV/AIDS & Cancer Virology, NCI (U.S.A); *Alessandro Marcello*, ICGBE, Trieste (Italy). **ViroStatics.**

**PARP INHIBITORS:** *Lari Lehtiö*, Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine University of Oulu (Finland); *Bernhard Lüscher*, Institute of Biochemistry and Molecular Biology, Aachen University, Aachen, (Germany), *Giovanna Grimaldi*, CNR Napoli (Italy)

**RNA as target:** *Michal Kolar*, Department of Physical Chemistry, University of Chemistry and Technology, Technicka, Prague (Czech Republic); *Paolo Carloni*, German Research School for Simulation Sciences Jülich, (Germany); *Gabriele Varani*, Department of Chemistry, University of Washington, Seattle, WA; *Barbara Gatto*, *Claudia Sissi*, Dipartimento di Scienze Farmaceutiche, Università di Padova, (Padova)

**ANTITUBERCULARS:** *Scott G. Franzblau*, Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Chicago (USA) *Gregory M Cook*, Department of Microbiology, University of Otago (NEW ZEALAND)

**PHARMACOKINETIC PROFILING:** *Jose Brea*, BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela (Spain); *Jadwiga Handzlik*, Department of Technology and Biotechnology of Drugs, Jagiellonian University, Krakow (Poland).

**COMPUTATIONAL STUDIES:** *Gabriele Cruciani* and *Laura Goracci*, Department of Chemistry, Biology, and Biotechnology, University of Perugia, (Italy); *Simona Distinto*, Dipartimento di Scienze Applicate ai Biosistemi, Cittadella Universitaria S.P. Monserrato-Cagliari (Italy)

**BIBLIOMETRIC DATA**

Scopus

publications: 139

citations: 4286

h-index: 38

Google Scholar

citations: 5330

h-index: 42

**SCIENTIFIC PUBLICATIONS**

1. G Nizi, S Massari, O Tabarrini, G Manfroni, G Manfroni. Interaction of medicinal chemistry overview of direct-acting antivirals approved in 2013-2024 by US FDA. *EJMedChem*, **2025**, 300, 118105.
2. J Alaviuhkola, MG Nizi, C Vagaggini, C Sarnari, B Lippok et al. Optimization of 2, 3-dihydrophthalazine-1, 4-dione PARP inhibitor scaffold for nanomolar potency and specificity towards human PARP10, *EJMedChem* **2025**, 300, 118111. Oriana Tabarrini
3. G Cernicchi, A Di Gregorio, T Felicetti, E Rampacci, G Casari, T Armeni, et al. NorA Efflux Pump Inhibitors: Expanding SAR Knowledge Pyrazolo[4,3-c][1,2]benzothiazine 5,5-Dioxide Derivatives, *Archiv der Pharmazie* **2025**, 358 (5), e70000
4. T Felicetti, CP Gwee, KWK Chan, G Pepe, C Milite, P Campiglia et al. New Pyridobenzothiazolone Derivatives Display Nanomolar Pan-Serotype Anti-Dengue Virus Activity. *ChemMedChem*, **2025**, 2500163
5. Felicetti, T, Di Iacovo, N, Della Fazia, M.A., Servillo, G, Manfroni, G. et al New anti-ovarian cancer quinolone derivatives acting by modulating microRNA processing machinery. *Rsc Medicinal Chemistry Open source preview*, **2025**, 16(1), pp. 98–124
6. Felicetti, T. Felicetti, T, Sarnari, C., Gaito, R, Tabarrini, O. Manfroni, G. Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents *J Med Chem* **2024**, 67(14), pp. 11543–11579
7. Cernicchi, Giada, Rampacci, Elisa Massari, Serena, Manfroni, Giuseppe Barreca, Maria Letizia, Tabarrini, Oriana Cecchetti, Violetta Felicetti, Tommaso Felicetti T.; Di Luca, Mariagrazia; Poma, Noemi Violeta Tavanti, Arianna Passamonti, Fabrizio Rindi, Laura Rindi L. Sabatini, Stefano. Discovery of 2-phenylquinazolines as potent Mycobacterium avium efflux pump inhibitors able to synergize with clarithromycin against clinical isolate. *Archiv der Pharmazie*, **2024**, 357(10), e2400296
8. Ghiandoni, GM, Flanagan, RS, Bodkin, MJ, Nizi, MG, Galera-Prat, A, Brai, A, Chen, B, Wallace, JEA, Hristozov, D, Webster, J, Manfroni; G, Lehtiö, L, **Tabarrini, O**, Gillet, VJ. Synthetically accessible de novo design using reaction vectors: Application to PARP1 inhibitors, *Mol Inform*, **2024**, 43(4), 183.
9. Pacetti, M, Pismataro, MC, Felicetti, T, Giammarino, F, Bonomini, A, Tiecco, M, Bertagnin, C, Barreca, ML, Germani, R, Cecchetti, V, Vicenti, I, **Tabarrini, O**, Zazzi, M, Loregian, A, Massari, S. Switching the three-component Biginelli-like reaction conditions for regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines, *Org Biomol Chem*, **2024**, 22(4), 767-783.
10. Bonomini, A., Felicetti, T. mPacetti, M. Loregian, A Massari, et al Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization. *Eur JMedChem*, **2024**, 277, 116737
11. Bonomini, A. Zhang, J. Ju, H. Zhan, P. Loregian, A Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo. *Antiviral Research*, **2024**, 230, 105980
12. Nizi, MG, Sarnari, C, **Tabarrini O**. Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs. *Molecules* **2023**, 28(15), 5849.
13. Murthy S, Nizi MG, Maksimainen MM, Massari S, Alaviuhkola J, Lippok BE, Vagaggini C, Sowa ST, Galera-Prat A, Ashok Y, Venkannagari H, Prunskaitė-Hyyryläinen R, Dreassi E, Lüscher B, Korn P, **Tabarrini O**, Lehtiö L. [1,2,4]Triazolo[3,4-b]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes. *J Med Chem*. **2023**, 66, 1301-1320
14. Astolfi A, Milano F†, Palazzotti D, Brea J , Pismataro MC, Morlando M, **Tabarrini O**, Loza I M, Massari S , Martelli MP and Barreca ML. From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia. *Pharmaceutics* **2022**, 14, 2295.
15. Nizi MG, Persoons L, Corona A, Felicetti T, Cernicchi G, Massari S, Manfroni G, Vangeel L, Barreca ML, Esposito F, Jochmans D, Milia J, Cecchetti V, Schols D, Neyts J, Tramontano E, Sabatini S, De Jonghe S, **Tabarrini O\***. Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. *ACS Med Chem Lett*. **2022** 13, 855-864.
16. Nizi MG, Maksimainen MM, Lehtiö L, **Tabarrini O\***. Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. *J Med Chem*. **2022** 65, 7532-7560.
17. Nizi MG, Maksimainen MM, Murthy S, Massari S, Alaviuhkola J, Lippok BE, Sowa ST, Galera-Prat A, Prunskaitė-Hyyryläinen R, Lüscher B, Korn P, Lehtiö L, **Tabarrini O\***. Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15. *Eur J Med Chem*. **2022**, 237, 114362.
18. Felicetti T, Cedraro N, Astolfi A, Cernicchi G, Mangiaterra G, Vaiaicca S, Massari S, Manfroni G, Barreca ML, **Tabarrini O**, Biavasco F, Cecchetti V, Vignaroli C, Sabatini S. New C-6 functionalized quinoline NorA inhibitors strongly synergize with ciprofloxacin against planktonic and biofilm growing resistant Staphylococcus aureus strains. *Eur J Med Chem*. **2022**, 241, 114656.
19. Felicetti T, Pismataro MC, Cecchetti V, **Tabarrini O\***, Massari S. Triazolopyrimidine nuclei: privileged scaffolds for developing antiviral agents with a proper pharmacokinetic profile. *Curr. Med. Chem*. **2022**. 29, 1379-1407.
20. Cedraro N, Cannalire R, Astolfi A, Mangiaterra G, Felicetti T, Vaiaicca S, Cernicchi G, Massari S, Manfroni G, **Tabarrini O**, Cecchetti V, Barreca ML, Biavasco F, Sabatini S. From Quinoline to Quinazoline-Based S. aureus NorA Efflux Pump Inhibitors by Coupling a Focused Scaffold Hopping Approach and a Pharmacophore Search. *ChemMedChem*. **2021**.
21. Pismataro MC, Felicetti T, Bertagnin C, Nizi MG, Bonomini A, Barreca ML, Cecchetti V, Jochmans D, De Jonghe S, Neyts J, Loregian A, **Tabarrini O**, Massari S. 1,2,4-Triazolo[1,5-a]pyrimidines: efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. *Eur. J. Med. Chem*. **2021**, 221:113494.

22. Massari S, Desantis J, Nizi MG, Cecchetti V, **Tabarrini O\***. Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. *ACS Infect. Dis.* **2021**, *7*, 1332-1350.
23. Felicetti T, Burali MS, Gwee CP, Ki Chan KW, Alonso S, Massari S, Sabatini S, **Tabarrini O**, Barreca ML, Cecchetti V, Vasudevan SG, Manfroni G. Sustainable, three-component, one-pot procedure to obtain active anti-flavivirus agents. *Eur. J. Med. Chem.* **2020**, *210*:112992.
24. Cannalire R, Mangiaterra G, Felicetti T, Astolfi A, Cedraro N, Massari S, Manfroni G, **Tabarrini O**, Vaiaicca S, Barreca ML, Cecchetti V, Biavasco F, Sabatini S. Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors. *Int. J. Mol Sci.* **2020**, *21*, 7037.
25. Nizi MG, Desantis J, Nakatani Y, Massari S, Mazzarella MA, Shetye G, Sabatini S, Barreca ML, Manfroni G, Felicetti T, Rushton-Green R, Hards K, Latacz G, Satała G, Bojarski AJ, Cecchetti V, Kolář MH, Handzlik J, Cook GM, Franzblau SG, **Tabarrini O\***. Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. *Eur. J. Med. Chem.* **2020**, *201*:112420.
26. Cannalire R, Ki Chan KW, Burali MS, Gwee CP, Wang S, Astolfi A, Massari S, Sabatini S, **Tabarrini O**, Mastrangelo E, Barreca ML, Cecchetti V, Vasudevan SG, Manfroni G. Pyridobenzothiazolones Exert Potent Anti-Dengue Activity by Hampering Multiple Functions of NS5 Polymerase. *ACS Med. Chem. Lett.* **2020**, *11*, 773-782.
27. Desantis J, Massari S, Corona A, Astolfi A, Sabatini S, Manfroni G, Palazzotti D, Cecchetti V, Pannecouque C, Tramontano E, **Tabarrini O\***. 1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. *Molecules* **2020**, *25*, 1183.
28. Felicetti T, Mangiaterra G, Cannalire R, Cedraro N, Pietrella D, Astolfi A, Massari S, **Tabarrini O**, Manfroni G, Barreca ML, Cecchetti V, Biavasco F, Sabatini S. C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors. *J. Enzyme Inhib. Med. Chem.* **2020**, *35*, 584-597.
29. Gargaro M, Vacca C, Massari S, Scalisi G, Manni G, Mondanelli G, Mazza EMC, Bicciato S, Pallotta MT, Orabona C, Belladonna ML, Volpi C, Bianchi R, Martino D, Iacono A, Panfili E, Proietti E, Iamandii IM, Cecchetti V, Puccetti P, **Tabarrini O**, Fallarino F, Grohmann U. Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells. *Front. Immunol.* **2019**, *10*, 1973.
30. Astolfi A, Kudolo M, Brea J, Manni G, Manfroni G, Palazzotti D, Sabatini S, Cecchetti F, Felicetti T, Cannalire R, Massari S, **Tabarrini O**, Loza MI, Fallarino F, Cecchetti V, Laufer SA, Barreca ML. Discovery of potent p38 $\alpha$  MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation. *Eur. J. Med. Chem.* **2019**, *182*, 111624.
31. Cannalire R, Tarantino D, Piorkowski G, Carletti T, Massari S, Felicetti T, Barreca ML, Sabatini S, **Tabarrini O**, Marcello A, Milani M, Cecchetti V, Mastrangelo E, Manfroni G, Querat G Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions. *Antiviral Res.* **2019**, *167*, 6-12.
32. Felicetti T, Machado D, Cannalire R, Astolfi A, Massari S, **Tabarrini O**, Manfroni G, Barreca ML, Cecchetti V, Viveiros M, Sabatini S. Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants *ACS Infect. Dis.* **2019**, *5*, 982-1000.
33. Desantis J, Massari S, Sosic A, Manfroni G, Cannalire R, Felicetti T, Pannecouque C, Gatto B, **Tabarrini O**. Design and synthesis of WM5 analogues as HIV-1 TAR RNA binders. *Open Med. Chem. J.* **2019**, *13*, 16-28.
34. Nannetti G, Massari S, Mercorelli B, Bertagnin C, Desantis J, Palù G, **Tabarrini O**, Loregian A. Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance. *Antiviral Res.* **2019**, *165*, 55-64.
35. Massari S, Corona A, Distinto S, Desantis J, Caredda A, Sabatini S, Manfroni G, Felicetti T, Cecchetti V, Pannecouque C, Maccioni E, Tramontano E, **Tabarrini O**. From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. *J. Enzyme Inhib. Med. Chem.* **2019**, *34*, 55-74.

36. Felicetti T, Cannalire R, Pietrella D, Latacz G, Lubelska A, Manfroni G, Barreca ML, Massari S, **Tabarrini O**, Kieć-Kononowicz K, Schindler BD, Kaatz GW, Cecchetti V, Sabatini S. 2-Phenylquinoline S. aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction. *J. Med. Chem.* **2018**, *61*, 7827-7848.
37. Murthy S, Desantis J, Verheugd P, Maksimainen MM, Venkannagari H, Massari S, Ashok Y, Obaji E, Nkizinkiko Y, Lüscher B, **Tabarrini O**, Lehtio L. 4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10. *Eur. J. Med. Chem.* **2018**, *156*, 93-102.
38. Felicetti T, Cannalire R, Nizi MG, **Tabarrini O**, Massari S, Barreca ML, Manfroni G, Schindler BD, Cecchetti V, Kaatz GW, Sabatini S. Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position. *Eur. J. Med. Chem.* **2018**, *155*, 428-433.
39. Matthes F, Massari S, Bochicchio A, Schorpp K, Schilling J, Weber S, Offermann N, Desantis J, Wanker E, Carloni P, Hadian K, **Tabarrini O\***, Rossetti G, Krauss S. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder. *ACS Chem. Neurosci.* **2018**, *9*, 1399-1408.
40. Nkizinkiko Y, Desantis J, Koivunen J, Haikarainen T, Murthy S, Sancineto L, Massari S, Ianni F, Obaji E, Loza MI, Pihlajaniemi T, Brea J, **Tabarrini O\***, Lehtiö L. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors. *SciRep.* **2018**, *8*:1680.
41. Iraci N, **Tabarrini O**, Santi C, Sancineto L. NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders. *Drug Discov. Today* **2018**, *23*, 687-695.
42. Cannalire R, Tarantino D, Astolfi A, Barreca ML, Sabatini S, Massari S, **Tabarrini O**, Milani M, Querat G, Mastrangelo E, Manfroni G, Cecchetti V. Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. *Eur. J. Med. Chem.* **2018**, *143*:1667-1676.
43. Sancineto L, Iraci N, **Tabarrini O**, Santi C. NCp7: targeting a multitasking protein for next-generation anti-HIV drug development part 1: covalent inhibitors. *Drug Discov. Today.* **2018**, *23*, 260-271.
44. **Tabarrini O**, Massari S. Acting on Tat-Mediated Transcription to Achieve a Long Term Control of HIV-1 Latency. *Curr. Pharm. Des.* **2017**, doi: 10.2174/138161282328171102111432.
45. Cannalire R, Machado D, Felicetti T, Santos Costa S, Massari S, Manfroni G, Barreca ML, **Tabarrini O**, Couto I, Viveiros M, Sabatini S, Cecchetti V. Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. *Eur. J. Med. Chem.* **2017**, *140*, 321-330.
46. Kolář MH, **Tabarrini O**. Halogen Bonding in Nucleic Acid Complexes. *J. Med. Chem.* **2017**, *60*, 8681-8690.
47. Massari S, Desantis J, Nannetti G, Sabatini S, Tortorella S, Goracci L, Cecchetti V, Loregian A, **Tabarrini O**. Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives. *Org. Biomol. Chem.* **2017**, *15*, 7944-7955.
48. Desantis J, Nannetti G, Massari S, Barreca ML, Manfroni G, Cecchetti V, Palù G, Goracci L, Loregian A, **Tabarrini O\***. Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. *Eur. J. Med. Chem.* **2017**, *138*, 128-139.
49. Felicetti T, Cannalire R, Burali MS, Massari S, Manfroni G, Barreca ML, **Tabarrini O**, Schindler BD, Sabatini S, Kaatz GW, Cecchetti V. Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues. *ChemMedChem.* **2017**, *12*, 1293-1302.
50. Machado D, Fernandes L, Costa SS, Cannalire R, Manfroni G, **Tabarrini O**, Couto I, Sabatini S, Viveiros M. Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against Escherichia coli. *PeerJ.* **2017**, *5*:e3168.
51. Astolfi A, Felicetti T, Iraci N, Manfroni G, Massari S, Pietrella D, **Tabarrini O**, Kaatz GW, Barreca ML, Sabatini S, Cecchetti V. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors. *J. Med. Chem.* **2017**, *60*, 1598-1604.
52. Massari S, Goracci L, Desantis J, **Tabarrini O**. Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Protein-protein Interaction as a Target for Next-generation Anti-influenza Therapeutics. *J. Med. Chem.* **2016**, *59*, 7699-7718.
53. **Tabarrini O\***, Desantis J, Massari S. Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV. *Future Med. Chem.* **2016**, *8*, 421-442.
54. Corona A, Desantis J, Massari S, Distinto S, Masaoka T, Sabatini S, Esposito F, Manfroni G, Maccioni E, Cecchetti V, Pannecouque C, Le Grice SF, Tramontano E, **Tabarrini O\***. Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors. *ChemMedChem.* **2016**, *11*, 1709-1720.

55. Mercorelli B, Luganini A, Nannetti G, **Tabarrini O**, Palù G, Gribaudo G, Loregian A. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication. *Cell Chem. Biol.* **2016**, *23*, 340-351.
56. Palomba M, Rossi L, Sancineto L, Tramontano E, Corona A, Bagnoli L, Santi C, Pannecouque C, **Tabarrini O**, Marini F. A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. *Org. Biomol. Chem.* **2016**, *14*, 2015-2024.
57. Sancineto L, Mariotti A, Bagnoli L, Marini F, Desantis J, Iraci N, Santi C, Pannecouque C, **Tabarrini O\***. Design and Synthesis of DiselenoBisBenzamides (DISEBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. *J. Med. Chem.* **2015**, *58*, 9601-9614.
58. Bochicchio A, Rossetti G, **Tabarrini O**, Krauß S, Carloni P. Molecular View of Ligands Specificity for CAG Repeats in Anti-Huntington Therapy. *J. Chem. Theory Comput.* **2015**, *11*, 4911-4922.
59. Machado D, Cannalire R, Costa SS, Manfroni G, **Tabarrini O**, Cecchetti V, Couto I, Viveiros M, Sabatini S, Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium. *ACS Infect. Dis.* **2015**, *1*, 593-603.
60. Franci G, Manfroni G, Cannalire R, Felicetti T, **Tabarrini O**, Salvato A, Barreca ML, Altucci L, Cecchetti V. Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives. *Cell Prolif.* **2015**, *48*, 705-717.
61. Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Palù G, Cruciani G, Loregian A, Goracci L, **Tabarrini O\***. A Broad Anti-Influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. *J. Med. Chem.* **2015**, *58*, 3830-3842.
62. Sabatini S, Manfroni G, Barreca ML, Bauer SM, Gargaro M, Cannalire R, Astolfi A, Brea J, Vacca C, Pirro M, Massari S, **Tabarrini O**, Loza MI, Fallarino F, Laufer SA, Cecchetti V. The pyrazolobenzothiazine core as a new chemotype of p38 alpha mitogen-activated protein kinase inhibitors. *Chem. Biol. Drug Des.* **2015**, *86*, 531-545.
63. Mercorelli B, Luganini A, Muratore G, Massari S, Terlizzi ME, **Tabarrini O**, Gribaudo G, Palù G, Loregian A. The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus that are Essential for Viral Replication. *Antimicrob. Agents Chemother.* **2014**, *58*, 6615-6626
64. Sancineto L, Iraci N, Barreca ML, Massari S, Manfroni G, Corazza G, Cecchetti V, Marcello A, Daelemans D, Pannecouque C, **Tabarrini O\***. Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. *Bioorg. Med. Chem.* **2014**, *22*, 4658-4666.
65. Donalisio M, Massari S, Argenziano M, Manfroni G, Cagno V, Civra A, Sabatini S, Cecchetti V, Loregian A, Cavalli R, Lembo D, **Tabarrini O**. Ethyl 1,8-Naphthyridone-3-carboxylates Downregulate Human Papillomavirus-16 E6 and E7 Oncogene Expression. *J. Med. Chem.*, **2014**, *57*, 5649-63.
66. Barreca ML, Iraci N, Manfroni G, Gaetani R, Guercini C, Sabatini S, **Tabarrini O**, Cecchetti V. Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. *J. Chem. Inf. Model.* **2014**, *54*, 481-497.
67. Manfroni G, Manvar D, Barreca ML, Kaushik-Basu N, Leyssen P, Paeshuyse J, Cannalire R, Iraci N, Basu A, Chudaev M, Zamperini C, Dreassi E, Sabatini S, **Tabarrini O**, Neyts J, Cecchetti V. New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. *J. Med. Chem.* **2014**, *57*, 3247-3262.
68. Royle CM, Tsai MH, **Tabarrini O**, Massari S, Graham DR, Aquino VN, Boasso A. Modulation of HIV-1-induced activation of plasmacytoid dendritic cells (pDCs) by 6-desfluoroquinolones. *AIDS Res. Hum. Retroviruses.* **2014**, *30*, 345-354.
69. Manfroni G, Cannalire R, Barreca ML, Kaushik-Basu N, Leyssen P, Winkvist J, Iraci N, Manvar D, Paeshuyse J, Guhamazumder R, Basu A, Sabatini S, **Tabarrini O**, Danielson UH, Neyts J, Cecchetti V. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. *J. Med. Chem.* **2014**, *57*, 1952-1963.
70. Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Facchini M, Palù G, Cruciani G, Loregian A, **Tabarrini O\***. Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. *J. Med. Chem.* **2013**, *56*, 10118-10131.

71. Sancineto L, Iraci N, Massari S, Attanasio V, Corazza G, Barreca ML, Sabatini S, Manfroni G, Avanzi NR, Cecchetti V, Pannecouque C, Marcello A, **Tabarrini O\***. Computer-Aided Design, Synthesis and Validation of 2-Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti-HIV-1 Tat-Mediated Transcription Activity. *ChemMedChem*. **2013**, *8*, 1941-1953.
72. Barreca M L, Manfroni G, Leyssen P, Winquist J, Kaushik-Basu N, Paeshuysse J, Krishnan R, Iraci N, Sabatini S, **Tabarrini O**, Basu A, Danielson UH, Neyts J, Cecchetti V. Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. *J. Med. Chem.* **2013**, *56*, 2270-2282.
73. Sancineto L, Massari S, Iraci N, **Tabarrini O\***. From Small to Powerful: The Fragments Universe and its "Chem-Appeal". *Curr. Med. Chem.* **2013**, *20*, 1355-1381.
74. Martelli A, Manfroni G, Sabbatini P, Barreca ML, Testai L, Novelli M, Sabatini S, Massari S, **Tabarrini O**, Masiello P, Calderone V, Cecchetti V. 1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions. *J. Med. Chem.* **2013**, *56*, 4718-4728.
75. Sabatini S, Gosetto F, Iraci N, Barreca ML, Massari S, Sancineto L, Manfroni G, **Tabarrini O**, Dimovska M, Kaatz GW, Cecchetti V. Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance. *J. Med. Chem.* **2013**, *56*, 4975-4989.
76. Massari S, Mercorelli B, Sancineto L, Sabatini S, Cecchetti V, Gribaudo G, Palù G, Pannecouque C, Loregian A, **Tabarrini O\***. Design, synthesis, and evaluation of WC5 analogues as inhibitors of human cytomegalovirus Immediate-Early-2 protein, a promising target for anti-HCMV treatment. *ChemMedChem*. **2013**, *8*, 1403-1414.
77. Massari S, Sabatini S, **Tabarrini O\***. Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery. *Curr. Pharm. Des.* **2013**, *19*, 1860-1879.
78. Pieroni M; Sabatini S, Massari, S, Kaatz, G , Cecchetti V, **Tabarrini O\***. Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. *MedChemComm*. **2012**, *3*, 1092-1097.
79. **Tabarrini O\***, Sabatini S, Massari S, Pieroni M, Franzblau SG, Cecchetti V. 6-Hydrogen-8-methylquinolones active against replicating and non-replicating Mycobacterium tuberculosis. *Chem. Biol. Drug Des.* **2012**, *5*, 781-786.
80. Sabatini S, Gosetto F, Serritella S, Manfroni G, **Tabarrini O**, Iraci N, Brincat JP, Carosati E, Villarini M, Kaatz GW, Cecchetti V. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors. *J. Med. Chem.* **2012**, *55*, 3568-3572.
81. **Tabarrini O\***, Massari S, Sancineto L, Daelemans D, Sabatini S, Manfroni G, Cecchetti V, Pannecouque C. Structural Investigation on naphthyridone scaffold: identification of 1,6-naphthyridone derivative with potent and selective anti-HIV activity. *ChemMedChem*. **2011**, *85*, 1392-1397.
82. Sabatini S, Gosetto F, Manfroni G, **Tabarrini O**, Kaatz GW, Patel D, Cecchetti. Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. *J. Med. Chem.* **2011**, *54*, 5722-5736.
83. Natalini B, Sardella R, Massari S, Ianni F, **Tabarrini O**, Cecchetti V. Synthesis and chromatographic enantioresolution of anti-HIV quinolone derivatives **2011**, *6*, 1249-57.
84. Manfroni G, Meschini F, Costantino F, **Tabarrini O**, Cecchetti V. N-Benzoyl-N-methylsulfonylanthranilates: unexpected cyclization reaction to 4-alkoxy-2,1-benzothiazines. *Arkivoc* **2011**, *9*, 165-176.
85. **Tabarrini O\***, Massari S, Daelemans D, Meschini F, Manfroni G, Bottega L, Gatto B, Palumbo M, Pannecouque C, Cecchetti V. Studies on anti-HIV transcription inhibitor quinolones: Identification of potent N1-vinyl derivatives. *ChemMedChem*. **2010**, *5*, 1880-1892.
86. **Tabarrini O\***, Massari S, Cecchetti V. 6-Desfluoroquinolones as HIV-1 Tat-Mediated Transcription Inhibitors. *Future Med. Chem.* **2010**, *2*, 1161-1180.
87. Loregian A, Mercorelli B, Muratore G, Sinigaglia E, Pagni S, Massari S, Gribaudo G, Gatto B, Palumbo M, **Tabarrini O**, Cecchetti V, Palù, G. The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein. *Antimicrob. Agents Chemother.* **2010**, *54*, 1930-1940.
88. Massari S, Daelemans D, Barreca M.L, Knezevich A, Sabatini S, Cecchetti V, Marcello A, Pannecouque C, **Tabarrini O\***. A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. *J. Med. Chem.* **2010**, *53*, 641-648.
89. Massari S, Daelemans D, Manfroni G, Sabatini S, **Tabarrini O\***, Pannecouque C, Cecchetti V. Studies on Anti-HIV Quinolones: New Insights on the C-6 Position. *Bioorg. Med. Chem.* **2009**, *17*, 667-674.

90. Mercorelli B, Muratore G, Sinigaglia E, **Tabarrini O**, Biasolo MA, Cecchetti V, Palu G, Loregian A. A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity. *Antimicrob. Agents Chemother.* **2009**, *53*, 312-315.
91. Manfroni G, Gatto B, **Tabarrini O**, Sabatini S, Cecchetti V, Giaretta G, Parolin C, Del Vecchio C, Calisti A, Palumbo M, Fravolini, A. Synthesis and Biological Evaluation of 2-Phenylquinolones Targeted at Tat/TAR Recognition *Bioorg. Med. Chem. Lett.* **2009**, *19*, 714-717.
92. Manfroni G, Paeshuyse J, Massar S, Gatto B, Zanolì S, Maga G, **Tabarrini O\***, Cecchetti V, Fravolini A, Neyts J. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. *J. Med. Chem.* **2009**, *52*, 3354-3365.
93. Gatto B, **Tabarrini O**, Massari S, Giaretta G, Sabatini S, Del Vecchio C, Parolin C, Fravolini A, Palumbo M, Cecchetti V. 2-Phenylquinolones as Inhibitors of the HIV-1 Tat/TAR Interaction. *Chem. Med. Chem.* **2009**, *4*, 935-938.
94. Spogli R, Sabatini S, Manfroni G, **Tabarrini O**, Cecchetti, V. Synthesis of 2-(Arylamino)ethanethiols via Lewis Acid catalyzed Aminolysis of 2,2-Dimethylthiirane as Precursors of the 1,4-Benzothiazine Nucleus. *Synthesis* **2009**, *9*, 1513-1519.
95. Calderone V, Spogli R, Martelli A, Manfroni G, Testai L, Sabatini S, **Tabarrini O**, Cecchetti V. Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca<sup>2+</sup>-Activated Potassium Channel Openers. *J. Med. Chem.* **2008**, *51*, 5085-5092.
96. **Tabarrini O\***, Massari S, Daelemans D, Stevens M, Manfroni G, Sabatini S, Balzarini J, Cecchetti V, Pannecouque, C, Fravolini A. Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. *J. Med. Chem.* **2008**, *51*, 5454-5458.
97. Paeshuyse J, Inge Vliegen I, Coelmont L, Leyssen P, **Tabarrini O**, Herdewijn P, Mittendorfer H, Easmon J, Cecchetti V, Bartenschlager R Puerstinger, G.; Neyts J. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. *Antimicrob. Agents Chemother.* **2008**, *52*, 3433-3337.
98. Stevens M, Pollicita M, Pannecouque C, Verbeken E, **Tabarrini O**, Cecchetti V, Acquaro S, Perno CF, Fravolini A, Schols D, De Clercq E; Balzarini, J. A Novel *in vivo* Model for the Study of HIV-1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives (6-DFQs). *Antimicrob. Agents Chemother.* **2007**, *4*, 1407-1413.
99. Cecchetti V, **Tabarrini O**, Sabatini S. From cromakalim to different structural classes of K<sub>ATP</sub> channel openers. *Curr. Top. Med. Chem.* **2006**, *6*, 1049-1068.
100. **Tabarrini O\***, Manfroni G, Fravolini A, Cecchetti V, Sabatini S, De Clercq E, Rozenski J, Canard B, Dutartre H, Paeshuys J, Neyts J. Synthesis and anti-BVDV activity of acridones as new potential antiviral agents. *J. Med. Chem.* **2006**, *49*, 2621-2627.
101. Dirk D, Pannecouque C, Pavlakis GN, **Tabarrini O**, De Clercq E. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors. *Mol. Pharmacol.* **2005**, *67*, 1574-1580.
102. Minelli A, Bellezza I, Siciliano E, Liguori L, **Tabarrini O**, Cecchetti V, Fravolini A. Inhibition of cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13. *Oncol. Rep.* **2005**, *13*, 1113-1120.
103. Carosati E, Lemoine H, Spogli R, Grittner D, Mannhold R, **Tabarrini O**, Sabatini S, Cecchetti V. Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type K<sub>ATP</sub>-channel openers. *Bioorg. Med. Chem.* **2005**, *13*, 5581-5591.
104. Stevens M, Balzarini J, **Tabarrini O**, Andrei G, Snoeck R, Cecchetti V, Fravolini A, De Clercq E, Pannecouque C. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. *J. Antimicrob. Chemother.* **2005**, *56*, 847-855.
105. Richter S, Gatto B, **Tabarrini O**, Fravolini A, Palumbo M. Antiviral 6-aminoquinolones: Molecular basis for potency and selectivity. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4247-4251.
106. Stevens M, **Tabarrini O**, Cecchetti V, De Clercq E, Fravolini A, Pannecouque C. Cell-dependent interference with viral transactivation by 6-aminoquinolone derivatives. *Antiviral Res.* **2005**, *65*, A55.
107. **Tabarrini O**, Stevens M, Cecchetti V, Sabatini S, Dell'Uomo M, Manfroni G, Palumbo M, Pannecouque C, De Clercq E, Fravolini A. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. *J. Med. Chem.* **2004**, *47*, 5567-5578.
108. Viola G, Facciolo L, Dall'Acqua S, Di Lisa F, Canton M, Vedaldi D, Fravolini A, **Tabarrini O**, Cecchetti V. 6-Aminoquinolones: Photostability, Cellular Distribution and Phototoxicity. *Toxicol. in Vitro*, **2004**, *18*, 581-592.
109. Cecchetti V, Calderone V, **Tabarrini O**, Sabatini S, Filipponi E, Testai L, Spogli R, Martinotti E, Fravolini A. Highly Potent 1,4-Benzothiazine Derivatives as K<sub>ATP</sub>-Channel Openers. *J. Med. Chem.* **2003**, *46*, 3670-3679.

110. Miolo G, Vedaldi D, Dall'Acqua F, Fravolini A, **Tabarrini O**, Cecchetti V. In vitro phototoxic properties of new 6-desfluoro-8-methylquinolones. *Toxicol. in Vitro*. **2002**, *16*, 683-693.
111. Filipponi E, Cruciani G, **Tabarrini O**, Cecchetti V, Fravolini A. 3D-QSAR study of anti-HIV quinolone library. *J. Comput. Aided Mol. Des.* **2001**, *15*, 203-217.
112. **Tabarrini O**, Cecchetti V, Temperini A, Filipponi E, Lamperti MG, Fravolini A. Velnacrine Thiaanalogue as Potential Agents for Treating Alzheimer's Disease. *Bioorg. Med. Chem.* **2001**, *9*, 2921-2928.
113. Filipponi E, Cecchetti V, **Tabarrini O**, Bonelli D, Fravolini A. Chemometric Rationalization of the Structural and Physicochemical Basis for Selective Cyclooxygenase-2 Inhibition: Toward More Specific Ligands. *J. Comput. Aided Mol. Des.* **2000**, *14*, 277-291.
114. Cecchetti V, Schiaffella F, **Tabarrini O**, Fravolini A. (1,4-Benzothiazinyloxy)alkylpiperazine Derivatives as Potential Antihypertensive Agents. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 465-468.
115. Hua M, Cecchetti V, **Tabarrini O**, Fravolini A. New 1,8-peri-Annellated Tricyclic Quinolone Antibacterials. *J. Heterocycl. Chem.* **2000**, *37*, 297-301.
116. Cecchetti V, Parolin C, Moro S, Pecere T, Filipponi E, Callistri A, **Tabarrini O**, Gatto B, Palumbo M, Fravolini A, Palù G. 6-Aminoquinolones as New Potential Anti-HIV Agents. *J. Med. Chem.* **2000**, *43*, 3799-3802.
117. **Tabarrini O**, Sissi C, Fravolini A, Palumbo M. 6-Hydroxy Derivative as New Desfluoroquinolone (DFQ): Synthesis and DNA-binding Study. *Nucleosides Nucleotides Nucleic Acids* **2000**, *19*, 1327-1336.
118. **Tabarrini O**, Cecchetti V, Fravolini A, Nocentini G, Barzi A, Sabatini S, Miao H, Sissi C. Design and Synthesis of Modified Quinolones as Antitumoral Acridones. *J. Med. Chem.* **1999**, *42*, 2136-2144.
119. De Sarro A, Cecchetti V, Fravolini A, **Tabarrini O**, Naccari F, De Sarro G. Effects of Novel 6-Desfluoroquinolones on Pentylentetrazole-induced Seizures in Mice. *Antimicrob. Agents Chemother.* **1999**, *43*, 1729-1736.
120. Sabatini S, Cecchetti V, **Tabarrini O**, Fravolini A. 8-Methyl-7-substituted-1,6-naphthyridine-3-carboxylic Acids as New 6-Desfluoroquinolone Antibacterials. *J. Heterocycl. Chem.* **1999**, *36*, 953-957.
121. Cecchetti V, **Tabarrini O**, Sabatini S, Miao H, Filipponi E, Fravolini A. Studies on 6-Aminoquinolones: Synthesis and Antibacterial Evaluation of 6-Amino-8-ethyl- and 6-Amino-8-methoxyquinolones. *Bioorg. Med. Chem.* **1999**, *7*, 2465-2471.
122. Cecchetti V, Fravolini A, Sabatini S, **Tabarrini O**, Xin T. Dibenzo[1,6]naphthyridinediones as Modified Quinolone Antibacterials. *Eur. J. Med. Chem.* **1998**, *33*, 899-903.
123. Cecchetti V, Filipponi E, Fravolini A, **Tabarrini O**, Bonelli D, Clementi M, Cruciani G, Clementi S. Chemometric Methodologies in a Quantitative Structure-Activity Relationship Study: the Antibacterial Activity of 6-Aminoquinolones. *J. Med. Chem.* **1997**, *40*, 1698-1706.
124. Cecchetti V, Cruciani G, Filipponi E, Fravolini A, **Tabarrini O**, Xin T. Synthesis and Antibacterial Evaluation of [1,3]Benzothiazino[3,2-a]quinoline and [3,1]Benzothiazino[1,2-a]quinoline-6-carboxylic Acid Derivatives. *Bioorg. Med. Chem.* **1997**, *5*, 1339-1344.
125. Carbone M, Fera MT, Cecchetti V, **Tabarrini O**, Losi E, Cusumano V, Teti G. In Vitro Activities of New Quinolones Against *Helicobacter pylori*. *Antimicrob. Agents Chemother.* **1997**, *41*, 2790-2792.
126. Cecchetti V, Fravolini A, Lorenzini MC, **Tabarrini O**, Terni P, Xin T. Studies on 6-Aminoquinolones: Synthesis and Antibacterial Evaluation of 6-Amino-8-methylquinolones. *J. Med. Chem.* **1996**, *39*, 436-445.
127. Cecchetti V, Fravolini A, Palumbo M, Sissi C, **Tabarrini O**, Terni P, Xin T. Potent 6-Desfluoro-8-methylquinolones as New Lead Compounds in Antibacterial Chemotherapy. *J. Med. Chem.* **1996**, *39*, 4952-4957.
128. Cecchetti V, Clementi S, Cruciani G, Fravolini A, Pagella PG, Savino A, **Tabarrini O**. 6-Aminoquinolones: A New Class of Quinolone Antibacterials? *J. Med. Chem.* **1995**, *38*, 973-982. 56
129. Wise R, Pagella PG, Cecchetti V, Fravolini A, **Tabarrini O**. In Vitro Activity of MF 5137, a New Potent 6-aminoquinolone. *Drugs* **1995**, *49*, 272-273.

130. Cecchetti V, Fravolini A, Pagella PG, **Tabarrini O**, Temperini A. 7-(Disubstituted Thiazolyl)-3,5-dihydroxy-6-Heptenoic/Hepatanic Acid Derivatives as HMG-CoA Reductase Inhibitors. *Bioorg. Med. Chem.* **1994**, 2, 799-806.
131. Cecchetti V, Fravolini A, Schiaffella F, **Tabarrini O**, Bruni G, Segre G. *o*-Chlorobenzenesulfonamidic Derivatives of (Aryloxy)propanolamines as  $\beta$ -Blocking/Diuretic Agents. *J. Med. Chem.* **1993**, 36, 157-161.
132. Cecchetti V, Fravolini A, Pagella PG, Savino A, **Tabarrini O**. Quinoline Carboxylic Acids. 3. Synthesis and Antibacterial Evaluation of 2-Substituted-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4]benzothiazine-6-carboxylic Acids Related to Rufloxacin. *J. Med. Chem.* **1993**, 36, 3449-3454.
133. Cecchetti V, Fravolini A, Fringuelli R, Schiaffella F, Lorenzini MC, **Tabarrini O**. 4*H*-1,4-Benzothioopyran-4-one-3-carboxylic Acids and 3,4-Dihydro-2*H*-isothiazolo[5,4-*b*][1]benzothiopyran-3,4-diones as Quinolone Antibacterial Analogs. *J. Heterocycl. Chem.* **1993**, 30, 1143-1148.
134. Cecchetti V, Fravolini A, Pagella PG, **Tabarrini O**, Zhou W. 1,4-Benzothiazine-2-carboxylic Acids 1-Oxide as Analogue of Antibacterial Quinolones. *J. Heterocycl. Chem.* **1992**, 29, 375-382.
135. Cecchetti V, Schiaffella F, **Tabarrini O**, Zhou W, Fravolini A, Goi A, Bruni G, Segre G. Symbiotic approach to drug design: *N*-[(4-chloro-3-sulfamoylbenzamido)-ethyl]propanolamine derivatives as  $\beta$ -adrenergic blocking agents with diuretic activity. *Eur. J. Med. Chem.* **1991**, 26, 381-386.

## PATENTS

- A. Lehtiö L, Maksimainen M, Murthy Sudarshan N, Tabarrini O, Nizi M.G., Massari S. "Compounds for use in the treatment of cancer and inflammatory conditions" Finnish Application No 20225073, filing date Jan, 28, **2022**; PCT/FI2023/050060, filing date Jan, 30, **2023**, WO 2023/144450 A1
- B. Loregian A, Palù G, Muratore G, Cruciani G, Tabarrini O. New inhibitors of influenza A and B viruses acting by disrupting PA and PB1 subunit interactions of heterotrimeric viral RNA polymerase. WO2013123974-A1, Aug, 29, **2013**.
- C. Loregian, A., Palù, G., Mercorelli, B., Tabarrini, O., Cecchetti, V. Compositions and methods for the treatment of the pathological condition(s) associated to cytomegalovirus infection" US provisional Application No 61/374.320 filing date Aug, 17, **2010**.
- D. Cecchetti, V.; Fravolini, A.; Tabarrini, O.; Terni, P.; Xin, T. Derivati Chinolonici non Fluorurati e Loro Impiego come Agenti Antibatterici. Brev. Italiano MI95A001593, **1995**.
- E. Cecchetti, V.; Fravolini, A.; Terni, P.; Pagella, P.G.; Tabarrini, O. 6-Aminoquinolones, their Synthesis and their Use as Antibacterial Agents. Eur. Pat. Appl. EP 531,958; Chem. Abstr. 119, **1993**, 139267.

## SCIENTIFIC HIGHLIGHTS

- The review "Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. Massari, S.; Desantis, J.; Nizi, M.G.; Cecchetti, V.; Tabarrini, O. *ACS Infect. Dis.* **2020**, 7,1332-1350." of which I'm the corresponding author was selected for the Front Cover Picture of the Special Issue "Antiviral Therapeutics" in ACS Infectious Disease (<https://pubs.acs.org/toc/aidcbc/7/6>)
- The article "Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. *J Med Chem.* 58, 3830-42, 2015" of which I'm the corresponding and senior author, was highlighted "of special interest" in Naesens L. et al "Antiviral therapies on the horizon for influenza". *Current Opinion in Pharmacology*, **2016**, 30, 106-115.
- The poster entitled "Design and synthesis of potent anti-influenza small molecules that disrupt the RNA polymerase PA-PB1 subunits interaction", of which I'm the senior author, was awarded at the "First WG Meeting COST ACTION CA15135 Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)", - Budapest (Ungary) dal 19-11-2016 al 20-11-**2016**.
- The article: "Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors. *ChemMedChem.* **2016**, 11, 1709-20, of which I'm the corresponding and senior author, was selected for the front cover picture of the journal.

- The article "Studies of Anti-HIV Transcription Inhibitor Quinolones: Identification of Potent N1-Vinyl Derivatives" *ChemMedChem* **2011**, *6 Special Issue: 1249-1257*, of which I'm the first and corresponding author, was mentioned in the front cover picture of the journal
- The article "A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication". *J. Med. Chem.* 2010, *53*, 641-64" of which I'm the corresponding and senior author, was mentioned in Science-business eXchange (BioCentury-Nature), 7.01.2010, vol3/number 1 (page 13).
- The article "Studies on anti-HIV transcription inhibitor quinolones: Identification of potent N1-vinyl derivatives" *ChemMedChem* **2010**, *5*, 1880-1892, of which I'm the corresponding author, was selected for the inside cover picture of the journal

## ORAL COMMUNICATIONS

- "New nicotinamide mimic scaffold allowed nanomolar inhibition of human PARP enzymes" XXVII National Meeting in Medicinal Chemistry, September 11-14, **2022** Bari (Italy), **OC9**
- "Exploiting a proprietary compound library to fight SARS-CoV-2: identification of 2-phenylquinolines with pan-anticoronavirus activity" Online meeting, 5th Innovative Approaches for Identification of Antiviral Agents Summer School, September, 22-24, **2021**, **OP35**
- "Cycloheptathiophene-3-carboxamide as useful sulfur-containing scaffold for inhibiting essential targets of HIV-1 and influenza virus" VII Encontro sobre Enxofre, Selenio e Telurio and 7th Workshop of SeS Redox and catalysis, September 2-6, **2018**, Santa Maria (Brasil), **ML**.
- "Exploiting the Anti-HIV 6-Desfluoroquinolones to Design Multiple Ligands". V EWDSy: European Workshop in Drug Synthesis. Maggio 18-23, **2014**, Siena, Italy, **OP**.
- "Targeting CDKs to inhibit the HIV-1 Tat-mediated transcription" XXII National Meeting on Medicinal Chemistry, September 10-13, **2013**, Roma – Italy, **OP-28**
- "HIV-1 Transcription Inhibitors for an Innovative Chemotherapeutic Intervention. XX National Meeting on Medicinal Chemistry". Padova, Italy, September 12-16, **2010**, **ML-13**.
- "Nuovi agenti anti-HIV: 6-aminochinoloni come inibitori del processo di transattivazione Tat-mediato". XVI Convegno Nazionale (Divisione di Chimica Farmaceutica, SCI). Sorrento, Italy, September 18-22, **2002**, **L-48**.
- "Cycloheptathiophene-3-carboxamide as useful scaffold for inhibiting essential targets within the influenza virus and HIV-1 replicative cycles." November, 9, **2018**. *Trinity College of Dublin* (Ireland).
- "HIV-1 Tat-mediated transcription as attractive intervention site for small molecules". *German Research School for Simulation Sciences GmbH, Julich* (Germany), October, 17-19, **2011**.
- "Quinolones as Tat-mediated transcription inhibitors. *Institut Cochin, Paris*, March, 19, **2007**.
- "New anti-HIV agents". International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, March, 14, **2007**.

Invited by research  
Institutes/Universities

## CONGRESS ORGANIZER

- |      |   |
|------|---|
| 2025 | First PANVIRIDE drug discovery conference, September 30, 2025, Catanzaro (Italy) ( <i>Organizer and Scientific Committee</i> )                                    |
| 2019 | VIII workshop of the network of multidisciplinary research "SeS Redox and Catalysis" Perugia, May 30-June 1 <sup>st</sup> 2019                                    |
| 2016 | XXIV National Meeting in Medicinal Chemistry and the 10th Young Medicinal Chemists Symposium "Nuove Prospettive in Chimica Farmaceutica", Perugia, September 2016 |
| 2015 | IV workshop of the network of multidisciplinary research "SeS Redox and Catalysis" Perugia, 20 and 21 April 2015  |
| 2014 | III workshop of the network of multidisciplinary research "SeS Redox and Catalysis" Perugia, September, 15-17, 2014   |
| 2011 | XXX TUMA, Perugia, Italy, June 30-July 1, 2011 ( <i>Organizer and Scientific Committee</i> )  |

Chair of sessions of "Meeting of the Paul Ehrlich Euro-PhD Network": July **2023** (XII ed Salonicco) July **2021** (virtual meeting), July **2018** (VII Ed, Porto, Portugal), July **2015** (V Ed, Cracovia, Polonia).

EDITORIAL AND REFEREE  
ACTIVITIES

- 2020 Editor of *Molecules*, <https://www.mdpi.com/journal/molecules/editors>.  
Editor of the special issue: "RNA: Still an Under-Exploited Drug Target" *Molecules*, section "Medicinal Chemistry", still open for submission.  
[https://www.mdpi.com/journal/molecules/special\\_issues/RNA\\_Drug\\_Target](https://www.mdpi.com/journal/molecules/special_issues/RNA_Drug_Target)
- 2016 Editor of the special issue entitled "Acting on Tat-mediated transcription to achieve a long term control of HIV-1 latency". *Current Pharmaceutical Design*, Volume 23, Issue 28, 2017 DOI: 10.2174/1381612823281711021114322016
- 2016 Editor of the "Open medicinal chemistry Journal" ISSN: 1874-1045.  
<https://www.benthamopen.com/TOMCJ/editorial-board>

**Referee of journals:** Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Bioorganic and Medicinal Chemistry Letters, Current Medicinal Chemistry, ChemMedChem, Amino Acids, ChemPharmBull, Future Medicinal Chemistry, Chemical Biology and Drug Design, Antiviral Research, Future Medicine, Chemistry Open, Biology, Letters of Organic Chemistry, Oncotarget, ACS Medicinal Chemistry Letters, Monatshefte für Chemie-Chemical Monthly, Journal of Enzyme Inhibition Medicinal Chemistry, Molecules.

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali"

Perugia January 9<sup>th</sup>, 2025

Signature

